Back to top

crispr: Archive

Zacks Equity Research

CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss

CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.

VRTXPositive Net Change UTHRPositive Net Change LGNDPositive Net Change CRSPPositive Net Change

Zacks Equity Research

Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?

Vertex's (VRTX) revenues in the first quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.

ALNYNegative Net Change VRTXPositive Net Change CRSPPositive Net Change ALPNPositive Net Change

Zacks Equity Research

Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss

Allogene's (ALLO) fourth-quarter earnings beat estimates, but sales miss the mark. Management expects operating expenses for 2024 to be around $280 million.

GSKPositive Net Change ANIPPositive Net Change ADMAPositive Net Change ALLOPositive Net Change